Genetix Biotherapeutics and SPIMACO Announce Strategic Agreement to Commercialize and Manufacture LYFGENIA™ & ZYNTEGLO™ in Saudi Arabia and the Broader Middle East Region
Genetix Biotherapeutics Inc. and the Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) and its wholly owned subsidiary, SPIMACO Bio, today announced an exclusive collaboration and license agreement for the development, commercialization, and localized manufacturing of LYFGENIA™ and ZYNTEGLO™ in Saudi Arabia and across the broader Middle East. LYFGENIA and ZYNTEGLO are first-in-class, one-time gene addition cell therapies for the treatment of children and adults with sickle cell disease and transfusion dependent beta-thalassemia, respectively.
Genetix Announces 2025 Commercial Performance Results and Outlines 2026 Strategic Priorities
Genetix Biotherapeutics Inc., the market leader in genetic therapies for hemoglobinopathies in the U.S., today announced commercial performance results from 2025 and outlined the company’s strategic priorities for 2026.
Genetix Presents Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting
Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLO™ and LYFGENIA™, first-in-class ex vivo gene addition therapies for the treatment of beta-thalassemia and sickle cell disease. With over 250 patients treated with these therapies, inclusive of clinical trials and commercial treatments, and long-term follow-up data beyond 10 years, Genetix has the most robust long-term dataset in ex vivo gene therapy for hemoglobinopathies.
Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program & Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation
Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida (December 6-9, 2025). Genetix’s abstract Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia was selected by the ASH Program Committee as one of the meeting’s most impactful datasets submitted this year.
Genetix Biotherapeutics to Present Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting
Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIA™ and ZYNTEGLO™ in the U.S. has been selected for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida (December 6-9, 2025).
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots
bluebird bio, Inc. today announced it has rebranded as Genetix Biotherapeutics Inc., returning to its foundational roots. Genetix, now strengthened both financially and operationally, is significantly better positioned to harness its decades of scientific innovation and extensive clinical data from hundreds of treated patients to more effectively deliver life-changing genetic therapies. The recently appointed Genetix management team, led by CEO David Meek, is committed to delivering on this mission. The company has three FDA-approved genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These first-in-class, one-time administered therapies target the root cause of disease and can offer significant and lasting benefits to patients.
